- Fucked Finance
- Posts
- Stock Tip Tuesday
Stock Tip Tuesday
$PALI: Low Float, High Heat, and a $14 PT?
Stock Tip Tuesday…
Nasdaq: $PALI ( ▼ 1.02% ) : Low Float, High Heat, and a $14 PT?

Disseminated on Behalf of Palisade Bio Inc.
Shamless Shill
This Stock Has The Potential to Fix Your Shit

Today we’re talking about Palisade Bio $PALI ( ▼ 1.02% ) - a Nasdaq-listed microcap that's swinging for the fences in the bowel disease game - micro float under 5M shares, machine learning-powered trials, and a $14 analyst target.
No, I am not shitting you and neither is this stock!
Anal-aysis
PALI’s Setup: Small Float. Big Pipe Dream.

You opened this email today to get shilled - so here you go:
$14 Analyst Target.
That’s 1600% upside. According to the research universe of Ladenburg Thalmann Co. Inc., they believe $PALI has the potential to reach $14.4.46M Float.
You know the drill, all the best things in life come tight. If we see successful human trials and this thing catches some attention, we could be in for some serious fun.Massive TAM (total addressable market)
The inflammatory Bowel Disease (IBD) market is projected to hit $31B by 2034.Drug Is in Human Trials NOW.
Topline data dropping end of May. One good PR and… you’ve seen these tight float biotechs in action - I don't have to tell you what could happen…
Anal-aysis
So, What Do They Actually Do?

Palisade’s lead asset PALI-2108, is a gut-restricted PDE4 inhibitor. That means it delivers its anti-inflammatory effect right where it’s needed, the colon, without blasting your whole body and frying your CNS.
Translation: Kills the colitis, and skips the side effects.
They’re also using machine learning to identify ideal patients for their trials, filtering out the fluff and zeroing in on responders like a sniper with AI.
Biotech x Silicon Valley - In the colon.
Anal-aysis
If You like TA, This Chart Setup Could be a Cooker

Lastly, if you geek out to a good TA setup, $PALI ( ▼ 1.02% ) just broke above its 5-day EMA, 13-day EMA, 20-day SMA, and 50-day SMA.
Thank you
That’s All Folks
Closing notes: This is a high-risk, potentially high-reward, low-float biotech heater entering a $31B+ market with machine learning-enhanced trials and a $14 price target.
If the May data drop hits? This thing could teleport.
But right now, it’s got everything we like:
Science
Machine learning
1600% PT
Micro float